Skip to main content

REVIEW article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1326033

The current landscape of the antimicrobial peptide melittin and its therapeutic potential

 Hai-Qian Zhang1 Chengbiao Sun1 Na Xu2* Wensen Liu1*
  • 1Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
  • 2Jilin Medical University, China

The final, formatted version of the article will be published soon.

Receive an email when it is updated
You just subscribed to receive the final version of the article

Melittin, a main component of bee venom, is a cationic amphiphilic peptide with a linear αhelix structure. It has been reported that melittin can exert pharmacological effects, such as antitumor, antiviral and anti-inflammatory effects in vitro and in vivo. In particular, melittin may be beneficial for the treatment of diseases for which no specific clinical therapeutic agents exist. Melittin can effectively enhance the therapeutic properties of some first-line drugs. Elucidating the mechanism underlying melittin-mediated biological function can provide valuable insights for the application of melittin in disease intervention. However, in melittin, the positively charged amino acids enables it to directly punching holes in cell membranes. The hemolysis in red cells and the cytotoxicity triggered by melittin limit its applications. Melittin-based nanomodification, immuno-conjugation, structural regulation and gene technology strategies have been demonstrated to enhance the specificity, reduce the cytotoxicity and limit the off-target cytolysis of melittin, which suggests the potential of melittin to be used clinically. This article summarizes research progress on antiviral, antitumor and anti-inflammatory properties of melittin, and discusses the strategies of melittin-modification for its future potential clinical applications in preventing drug resistance, enhancing the selectivity to target cells and alleviating cytotoxic effects to normal cells.

Keywords: Melittin, Pharmacological effect, nanomodification, immuno-conjugation, Structural regulation, gene technology strategies

Received: 22 Oct 2023; Accepted: 03 Jan 2024.

Copyright: © 2024 Zhang, Sun, Xu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Prof. Na Xu, Jilin Medical University, Jilin, Jilin, China
Prof. Wensen Liu, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China